Search Results

You are looking at 31 - 40 of 85 items for :

  • Refine by Access: All content x
Clear All
Open access

Jothydev Kesavadev, Pradeep Babu Sadasivan Pillai, Arun Shankar, Gopika Krishnan, and Sunitha Jothydev

, thiazolidinediones (TZDs), gliptins, GLP-1 analogs or gliflozins may be employed ( 21 ). The use of these traditional agents may be limited, however, because of several factors. Biguanides and TZDs improve the insulin resistance, but do not address the progressive

Open access

Ulrik Ø Andersen, Dijana Terzic, Nicolai Jacob Wewer Albrechtsen, Peter Dall Mark, Peter Plomgaard, Jens F Rehfeld, Finn Gustafsson, and Jens P Goetze

and water, and also via vasodilatory effects. Importantly, it has also been shown that sacubitril/valsartan reduces the mortality for patients with chronic heart failure ( 3 ). Several other hormones, for instance glucagon-like peptide-1 (GLP-1) and

Open access

Espen Nordheim and Trond Geir Jenssen

beneficial effects in patients with kidney disease beyond the blood-glucose lowering effect: receptor agonists of the glucagon-like protein 1 receptor (GLP-1 RA) and inhibitors of sodium-glucose-co-transporter-2 (SGLT2i). In secondary analyses of the SAVOR

Open access

Meena Asmar, Ali Asmar, Lene Simonsen, Flemming Dela, Jens Juul Holst, and Jens Bülow

indicate that GIP receptor expression in subcutaneous adipose tissue is inversely associated with BMI ( 35 , 36 ). Interestingly, the other incretin hormone, glucagon-like-peptide-1 (GLP-1), also increases total blood flow in adipose tissue in healthy

Open access

Alexis Sudlow, Carel W le Roux, and Dimitri J Pournaras

loss produced by the initial operation involving the removal of a segment of the stomach prompted surgeons to undertake it as a procedure in its own right. The metabolic effects of SG are thought to be the result of a combination of increased GLP-1 and

Open access

Wenrui Wang and Chuan Zhang

; Peptide (GLP-1) Similar developmental background to β-cells in vivo ; Large proportion and flexible plasticity; Share quantity of transcription factors; Corresponding metabolic mechanism and hormone secretion Low conversion rate; Weak proliferative

Open access

Mônica R Gadelha, Feng Gu, Marcello D Bronstein, Thierry C Brue, Maria Fleseriu, Ilan Shimon, Aart J van der Lely, Shoba Ravichandran, Albert Kandra, Alberto M Pedroncelli, and Annamaria A L Colao

greater degree than glucagon, which results in increased glucose levels ( 19 ). Indeed, pasireotide has been shown to reduce secretion of insulin, glucagon, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide in healthy volunteers

Open access

Sakina H Bharmal, Wandia Kimita, Juyeon Ko, and Maxim S Petrov

centrifuged at 4000 g for5.5 min at 4°C, plasma separated, aliquoted, and stored at −80°C for future analyses.Amylin, C-peptide, glucagon, glucose-dependent insulinotropic peptide (GIP), glucagon-like peptide-1 (GLP-1), insulin, pancreatic polypeptide, and

Open access

Peter Wolf, Alexandre Dormoy, Luigi Maione, Sylvie Salenave, Jacques Young, Peter Kamenický, and Philippe Chanson

development of hyperglycemia in 8 patients (23.5%). In two patients (14%), diabetes was treated by a s.c. injection of glucagon-like-peptide-1 (GLP-1) analog, and three patients (21%) received insulin. All other patients were treated by oral antidiabetic

Open access

Chunliang Yang, Junyi Li, Fei Sun, Haifeng Zhou, Jia Yang, and Chao Yang

, 2 ). Existing therapeutics are aimed at lowering blood glucose level by stimulating insulin secretion (direct: sulfonylureas, nateglinide; indirect: DPP-4 inhibitors/GLP-1), alleviating peripheral insulin resistance (Metformin, TZDs), reducing